Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

West Coast Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,708,658

305 payments

Through program year 2025, West Coast Research LLC is reported as receiving $2,708,658 in research payments, across 305 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $379,706 97
2024 Research $632,748 46
2023 Research $473,580 67
2022 Research $541,233 31
2021 Research $449,163 35
2020 Research $231,333 28
2019 Research $895 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $1,630,041 72 payments
  2. Amgen Inc. $407,513 25 payments
  3. AbbVie, Inc. $399,408 59 payments
  4. Seqirus USA Inc $216,261 81 payments
  5. Novartis Pharmaceuticals Corporation $33,164 4 payments
  6. Alnylam Pharmaceuticals Inc. $15,246 62 payments
  7. Vanda Pharmaceuticals Inc. $7,000 1 payment
  8. Moderna TX, Inc. $26 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Study to Evaluate the Efficacy Immunogenicity and Safety of Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults $1,300,677 50 payments
  2. A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age $208,524 77 payments
  3. A Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Infectious Respiratory Illnesses Including Covid19 and RSV in Healthy Individuals $173,026 7 payments
  4. A Phase 23 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Vaccine Candidates for Sarscov2 New Variants in Healthy Individuals $124,851 9 payments
  5. 20170625_Vesalius - CV $123,189 6 payments
  6. M16-100 $104,245 15 payments
  7. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $94,354 13 payments
  8. M19-161 $69,989 6 payments
  9. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $67,978 12 payments
  10. A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) $61,165 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record